ARDS Aridis Pharmaceuticals
- 0.060
- -0.003-4.00%
Aridis Pharmaceuticals News
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders Until January 12, 2024
Aridis Pharmaceuticals, Inc. (OTC QB: ARDS) today announced that its 2023 Annual Meeting of Stockholders ("Annual Meeting"), scheduled for Friday, December 15, 2023, was convened and adjourned, without any business being conducted, due to lack of the requisite quorum.
HC Wainwright & Co. Reiterates Buy on Aridis Pharmaceuticals, Maintains $2 Price Target
HC Wainwright & Co. analyst Vernon Bernardino reiterates Aridis Pharmaceuticals (OTC:ARDS) with a Buy and maintains $2 price target.
Promising Developments and Value Proposition: A Buy Rating Analysis of Aridis Pharmaceuticals
Aridis Pharmaceuticals Q3 EPS $0.00 Up From $(0.47) YoY, Sales $417.00K Up From $399.00K YoY
Aridis Pharmaceuticals Q3 EPS $0.00 Up From $(0.47) YoY, Sales $417.00K Up From $399.00K YoY
Aridis Pharmaceuticals Price Target Cut to $2.00/Share From $10.00 by HC Wainwright & Co.
Aridis Pharmaceuticals Price Target Cut to $2.00/Share From $10.00 by HC Wainwright & Co.
Aridis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Aridis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Aridis Pharmaceuticals, Lowers Price Target to $2
HC Wainwright & Co. analyst Vernon Bernardino maintains Aridis Pharmaceuticals with a Buy and lowers the price target from $10 to $2.
Aridis Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 10/20/2023 3821.57% HC Wainwright & Co. $10 → $2 Maintains Buy 01/26/2023 19507.84% HC Wainwright & Co. $1
FDA's Qualified Infectious Disease Product Designation Bolsters Aridis Pharmaceuticals' Investment Appeal: An Analyst's Buy Recommendation
Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / September 22, 2023 / RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChi
Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report on Bloomberg TV
Aridis Pharmaceuticals Announces $2 Million Offering to Fund Working Capital Needs
Aridis Pharmaceuticals Announces $2 Million Offering
Aridis Pharmaceuticals, Inc. (OTC: ARDS) today announced the pricing of an offering of 10,000,000 shares of the Company's common stock and accompanying warrants to purchase up to 10,000,000 shares of common stock at a combined offering price of $0.20 per share of common stock and accompanying warrant.
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersEtao International Co (NASDAQ:ETAO) shares rose 10.3% to $0.48 during Tuesday's after-market session. The market value of their outstanding shares is at $49.1 million. Virax Biolabs Group (NASD
Sector Update: Health Care Stocks Steady Premarket Tuesday
Health care stocks were steady premarket Tuesday as the Health Care Select Sector SPDR Fund (XLV) was up a slight 0.1% and iShares Biotechnology ETF (IBB) was flat. Masimo (MASI) was slipping past 28%
Why Are Aridis Pharmaceuticals Shares Moving Higher Today?
Aridis Pharmaceuticals Inc (NASDAQ:ARDS) shares are gaining after announcing positive European Medicines Agency feedback on its proposed single confirmatory Phase 3 study of investigational monoclonal
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersBiophytis (NASDAQ:BPTS) shares increased by 45.2% to $3.21 during Tuesday's pre-market session. The market value of their outstanding shares is at $9.9 million. Aridis Pharmaceuticals (NASDAQ:A
Update: Aridis Pharmaceuticals, European Regulator Agree on Pneumonia Phase 3 Study Parameters; Shares Jump Premarket
(Updates with the stock move in the headline and the last paragraph.) Aridis Pharmaceuticals (ARDS) said late Monday it reached an agreement with the European Medicines Agency on the overall design, e
12 Health Care Stocks Moving In Monday's After-Market Session
GainersAridis Pharmaceuticals (NASDAQ:ARDS) shares increased by 89.5% to $0.5 during Monday's after-market session. At the close, Aridis Pharmaceuticals's trading volume reached 8.1 million shares. Th
Aridis Pharmaceuticals Reaches Agreement for Phase 3 Study of Pneumonia Treatment in Europe; Shares Jump After Hours
Aridis Pharmaceuticals (ARDS) said late Monday it reached an agreement with the European Medicines Agency on the overall design, endpoints, and patient populations in its proposed single confirmatory
Analysis
Price Target
No Data
